Tingkat Keberhasilan Terapi Radioiodin Pertama pada Pasien Graves’ Disease

Aliya Khadijah Kemaleratu; Yuliana Rahmah Retnaningrum; Yudanti Riastiti

doi:10.30872/jsk.v6i1.673

Authors

Aliya Khadijah Kemaleratu Mulawarman University Author
Yuliana Rahmah Retnaningrum Laboratorium Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Mulawarman Author https://orcid.org/0009-0000-8685-5541 (unauthenticated)
Yudanti Riastiti Laboratorium Radiologi, Fakultas Kedokteran, Universitas Mulawarman Author

DOI:

https://doi.org/10.30872/jsk.v6i1.673

Keywords:

Graves' Disease, Radioiodin, Ablasi, Penyerapan Tc99m

Abstract

Graves’ Disease merupakan gangguan autoimun yang menyebabkan peningkatan sekresi hormon tiroid. Salah satu pengobatannya adalah terapi radioiodin / ablasi dengan sodium iodida-131. Penelitian ini untuk mengetahui tingkat keberhasilan pasien Graves’ Disease yang menjalani ablasi tiroid pertama. Desain penelitian ini adalah deskriptif observasional dengan pendekatan cross-sectional. Data penelitian didapatkan dari rekam medik pasien di Instalasi Kedokteran Nuklir Rumah Sakit Umum Daerah Abdoel Wahab Sjahranie Samarinda periode 2018-2023. Jumlah sampel yang didapatkan sebanyak 90 pasien. Hasil terapi menunjukkan 45.5% pasien tetap hipertiroid. Kriteria usia < 40 tahun sebanyak 60%, dan usia >= 40 tahun sebanyak 40%, dengan rerata 37 tahun; jenis kelamin laki-laki sebanyak 19%, dan perempuan 81%; rerata nilai radioaktivitas dengan penyerapan Technetium-99m pertechnetate sebelum terapi sebesar 19%, dan sesudah terapi sebesar 6.62%; sesudah terapi, kadar hormon tiroid yang rendah dicapai oleh 15.5% dari jumlah sampel, normal 39%, dan tinggi 45.5%. Keberhasilan ablasi dicapai oleh 29% pasien.

References

[1] Khan, M. S., Lone, S. S., Faiz, S., Farooq, I., & Majid, S., 2021, Graves’ Disease: Pathophysiology, Genetics and Management, IntechOpen.

[2] Kim, M. J., Cho, S. W., Kim, Y. A., Choi, H. S., Park, Y. J., Park, D. J., & Cho, B. Y., 2022, Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease. Endocrinology and Metabolism.

[3] Pedoman Pengelolaan Penyakit Hipertiroid, 2017, PERKENI.

[4] RISKESDAS 2013 Provinsi Kalimantan Timur, 2013.

[5] Camara, M., Diawara, O., Camara, T., Ekoba, F., Choukrallah, H., El Jamili, M., El Rhanbaz, S., 2023, Heart Complications of Graves' disease: About 2 Cases. SAS Publishers.

[6] Subekti, I., & Pramono, L. A., 2018, Current Diagnosis and Management of Graves’ Disease, Acta Medica Indonesiana.

[7] Lestary, A. R., Ahda, F. R., Cakra, I. A., Puspita, N. S., & Triani, E., 2023, Graves Disease: Diagnosis dan Tatalaksana, Lombok Medical Journal.

[8] Kim, H. J., 2023, Long-term management of Graves disease: a narrative review, Journal of Yeungnam Medical Science.

[9] Affandi, R. E., 2022, Perhimpunan Kedokteran Nuklir dan Teranostik Molekuler Indonesia. Diambil kembali dari Kedokteran Nuklir dan Teranostik Molekuler RSUP DR. Hasan Sadikin Dulu, Sekarang & Akan Datang.

[10] Rohmah, K., 2023, DISKOMINFO KALTIM. Diambil kembali dari Hanya Ada 8 di Indonesia, RSUD AWS Miliki Layanan Kedokteran Nuklir.

[11] Croker, E. E., McGrath, S. A., & Rowe, C. W., 2021, Thyroid disease Using diagnostic tools effectively, The Royal Australian College of General Practitioners.

[12] Husseni, M. A.-K.-S., 2016, The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves’ Disease and the Predictive Factors Influencing its Development, World Journal of Nuclear Medicine.

[13] Bonnema, S. J., & Hegedüs, L., 2012, Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome, PubMed.

[14] Hu, R. T., Liu, D. S., & Li, B., 2020, Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients, BMC Endocrine Disorders.

[15] Hollenberg, A., & Wiersinga, W. M., 2020, Hyperthyroid Disorders. Dalam S. Melmed, R. J. Auchus, A. B. Goldfine, R. J. Koenig, & C. J. Rosen, Williams Textbook of Endocrinology 14th Edition, Elsevier.

[16] Simmonds, M. J., Kavvoura, F. K., Brand, O. J., Newby, P. R., Jackson, L. E., Hargreaves, C. E., Gough, S. C., 2014, Skewed X Chromosome Inactivation and Female Preponderance in Autoimmune Thyroid Disease: An Association Study and Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism.

[17] Yang, D., Xue, J., Ma, W., Liu, F., Fan, Y., Rong, J., Yu, Y., 2018, Prognostic factor analysis in 325 patients with Graves’ disease treated with radioiodine therapy, Nuclear Medicine Communications.

[18] Currie, G. M., & Iqbal, B., 2021, Remodeling 99mTc-Pertechnetate Thyroid Uptake: Statistical, Machine Learning, and Deep Learning Approaches, JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY.

[19] Fanning, E., Inder, W. J., & Mackenzie, E., 2018, Radioiodine treatment for graves’ disease: a 10-year Australian cohort study, BMC Endocrine Disorders.

[20] Wong, K. K., Shulkin, B. L., Gross, M. D., & Avram, A. M., 2018, Efficacy of radioactive iodine treatment of graves’ hyperthyroidism using a single calculated 131I dose, Clinical Diabetes and Endocrinology.

[21] Lina, Z., Wenqi, Z., Yubo, X., Qiang, W., Lin, B., Feng, G., & Bin, J., 2018, 99mTc-pertechnetate thyroid scintigraphy predicts clinical outcomes in personalized radioiodine treatment for Graves’ disease, Española de Medicina Nuclear e Imagen Molecular.

[22] Fang, Y., Du, W.-H., Zhang, C.-X., Zhao, S.-X., Song, H.-D., Gao, G.-Q., & Dong, M., 2021, The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease, BMC Endocrine Disorders.

[23] Mena, A. K., & Kabadi, U. M., 2021, Serum Free T4 Concentration: More Accurate and Reliable than TSH as an Indicator of Thyroid Gland Function, Fortune Journals.